Lantheus Holdings (LNTH) Cash & Equivalents (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Cash & Equivalents of $498.6 million for Q1 2026, down 46.88% year-over-year from $938.5 million in Q1 2025, and up 38.83% quarter-over-quarter from $359.1 million in Q4 2025.
Lantheus Holdings (LNTH) Cash & Equivalents (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Cash & Equivalents for 13 consecutive years, with $498.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 46.88% year-over-year to $498.6 million; the TTM figure through Mar 2026 stood at $498.6 million (down 46.88% YoY), while the FY2025 annual figure was $359.1 million, down 60.66% from the prior year.
- Cash & Equivalents climbed to $498.6 million in Q1 2026 per LNTH's latest filing, from $359.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $938.5 million in Q1 2025 and bottomed at $105.4 million in Q1 2022.
- Historically, Cash & Equivalents has averaged $546.5 million across 5 years, with a median of $498.6 million in 2026.
- Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 346.93% — and 2025, when it sank 60.66%.
- Lantheus Holdings' Cash & Equivalents stood at $415.7 million in 2022, then surged by 71.7% to $713.7 million in 2023, then rose by 27.91% to $912.8 million in 2024, then tumbled by 60.66% to $359.1 million in 2025, then jumped by 38.83% to $498.6 million in 2026.
- Business Quant data shows LNTH's Cash & Equivalents at $498.6 million in Q1 2026, $359.1 million in Q4 2025, and $382.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 593.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 593.30 Mn |
| Mar 31, 2026 | 498.58 Mn |
| Dec 31, 2025 | 359.12 Mn |
| Sep 30, 2025 | 382.01 Mn |
| Jun 30, 2025 | 695.57 Mn |
| Mar 31, 2025 | 938.53 Mn |
| Dec 31, 2024 | 912.81 Mn |
| Sep 30, 2024 | 866.39 Mn |
| Jun 30, 2024 | 757.02 Mn |
| Mar 31, 2024 | 718.28 Mn |
| Dec 31, 2023 | 713.66 Mn |
| Sep 30, 2023 | 614.13 Mn |
| Jun 30, 2023 | 414.08 Mn |
| Mar 31, 2023 | 470.86 Mn |
| Dec 31, 2022 | 415.65 Mn |
| Sep 30, 2022 | 257.26 Mn |
| Jun 30, 2022 | 171.43 Mn |
| Mar 31, 2022 | 105.36 Mn |
| Dec 31, 2021 | 98.51 Mn |
| Sep 30, 2021 | 91.48 Mn |